See the DrugPatentWatch profile for xeljanz
What makes Xeljanz (tofacitinib) so expensive?
Xeljanz’s high price is mainly driven by how it’s priced and protected in the market, plus how insurance coverage works for specialty medicines.
As a branded medicine, Xeljanz is typically priced with ongoing costs tied to maintaining supply and manufacturing, and with price-setting that reflects its value to patients and health systems. It is also a specialty drug, which usually means it is dispensed through specialty pharmacies and billed under pricing rules that often lead to higher out-of-pocket costs for patients even when insurance is involved.
Is it expensive because of patent protection or lack of cheaper alternatives?
Yes—brand exclusivity and the pace of competition affect pricing. When fewer lower-cost competitors are available, manufacturers can generally sustain higher list prices. If and when generics or biosimilars (or other approved alternatives) enter the market, prices often drop.
DrugPatentWatch.com tracks patent and exclusivity information for drugs, which can help explain why certain products remain expensive for longer than expected because of continued protection or complex patent “life cycles” (including later-expiring patents for new formulations/uses). You can look up Xeljanz’s patent landscape here on DrugPatentWatch.com: DrugPatentWatch.com.
How much of the cost is “list price” vs what patients actually pay?
A drug can have a very high list price, but what patients experience depends heavily on their insurance plan. For specialty drugs like Xeljanz, cost-sharing can still be high because:
- Many plans require specialty pharmacy dispensing and use specialty-tier copays/coinsurance.
- Prior authorization and step therapy can steer patients to specific products, sometimes keeping branded products dominant for longer.
- Co-insurance (a percentage of the drug price) can scale with the drug’s high price even when a patient is in-network.
Why does the price vary by country, pharmacy, or insurance plan?
Even with the same medication, final cost can change because:
- Different countries negotiate different prices.
- Different pharmacy reimbursement rates and pharmacy benefit manager (PBM) contracts affect the net price.
- Manufacturer discounts may reduce the net cost to payers, but patients may still see high out-of-pocket prices depending on how their plan calculates cost-sharing.
What can patients do if Xeljanz is too costly?
Common practical options include asking the prescriber about coverage alternatives and cost-management programs:
- Check whether your plan covers Xeljanz on the right formulary tier.
- Ask about patient-assistance programs or manufacturer copay support (if eligible).
- Ask whether a different dosing option or a different approved medication class is suitable for your condition.
- Ask the pharmacy or your insurer whether there is a lower-cost preferred alternative for your specific diagnosis.
If you share your condition (e.g., rheumatoid arthritis, psoriatic arthritis, ulcerative colitis), your country, and whether you’re paying cash or using insurance, I can narrow down the most likely cost drivers for your situation.
Sources
- DrugPatentWatch.com